Hemoglobin Level Analysis in Hemodialysis Patients Treated With Erythropoiesis Stimulating Agents

2010 ◽  
pp. 145-164
Author(s):  
J. D. Martín ◽  
Emilio Soria ◽  
A. Soldevila ◽  
M. Climente ◽  
L. M. Pallardó ◽  
...  
Keyword(s):  
Neural Network ◽  
End Stage Renal Disease ◽  
Network Models ◽  
Hemodialysis Patients ◽  
Hemoglobin Level ◽  
Neural Network Models ◽  
Self Organizing Maps ◽  
Stage Renal Disease ◽  
End Stage ◽  
Level Analysis

In this chapter authors try to develop an expert system with the help of neural network method like Organizing Maps (SOMs) for hemodialysis patient.  Neural network models play a very important role for data analysis of hemodialysis patients with end-stage renal disease.  There are two main goals: firstly, the knowledge extraction from a database using Self-Organizing Maps (SOMs); and secondly, to provide an accurate prediction of Hb levels next month.

Depression in end-stage renal disease hemodialysis patients

2006 ◽  
Vol 2 (12) ◽  
pp. 678-687 ◽  
Author(s):  
Daniel Cukor ◽  
Rolf A Peterson ◽  
Scott D Cohen ◽  
Paul L Kimmel
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Correlation between Calcium Phosphorus Product and Mean Arterial Pressure among Hemodialysis Patients with End Stage Renal Disease

2020 ◽  
Vol 5 (1) ◽  
Author(s):  
Muhammad Nadeem ◽  
Mansoor Abbas Qaisar ◽  
Ali Hassan Al Hakami ◽  
Fateh Sher Chattah ◽  
Muhammad Muzammil ◽  
...  
Keyword(s):  
Mean Arterial Pressure ◽  
Arterial Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Age Group ◽  
Calcium Phosphorus ◽  
The Mean ◽  
Stage Renal Disease ◽  
End Stage

Background: The mean arterial pressure serves as an expression of blood pressure in patients on chronic hemodialysis. Serum calcium phosphorus product is considered as a risk factor of vascular calcification that is associated with hypertension in the patients of end stage renal disease. The literature regarding this relationship is inconsistent therefore this study is designed to determine the correlation between calcium phosphorus product and mean arterial pressure among hemodialysis patients with end stage renal disease. Methods: A total of 110 patients of end stage renal disease on hemodialysis for at least one year, 20 to 60 years of age were included. Patients with primary or tertiary hyperparathyroidism, peripheral vascular disease, malignancy, hypertension secondary to any cause other than kidney disease were excluded. Mean arterial pressure was calculated according to the standard protocol in lying position. Blood samples for estimation of serum calcium and phosphorous were taken and was sent immediately to the laboratory for serum analysis. Results: Mean age was 44.17 ± 10.94 years. Mean calcium phosphorous product was 46.71 ± 7.36 mg/dl and mean arterial pressure was 103.61 ± 12.77 mmHg. The values of Pearson correlation co-efficient (r) were 0.863 for age group 20 to 40 years and 0.589 for age group 41 to 60 years. This strong positive correlation means that high calcium phosphorous product goes with high mean arterial pressure (and vice versa) for both the age groups. Conclusion: A strong positive relationship exists between the mean arterial pressure and calcium phosphorous product and is independent of patients’ age.

scholarly journals SOM-based aggregation for graph convolutional neural networks

2020 ◽  
Author(s):  
Luca Pasa ◽  
Nicolò Navarin ◽  
Alessandro Sperduti
Keyword(s):  
Neural Network ◽  
Network Models ◽  
Predictive Performance ◽  
Aggregation Operator ◽  
Graph Representation ◽  
Approximation Properties ◽  
Neural Network Models ◽  
Self Organizing Maps ◽  
Node Level ◽  
Real World Datasets

AbstractGraph property prediction is becoming more and more popular due to the increasing availability of scientific and social data naturally represented in a graph form. Because of that, many researchers are focusing on the development of improved graph neural network models. One of the main components of a graph neural network is the aggregation operator, needed to generate a graph-level representation from a set of node-level embeddings. The aggregation operator is critical since it should, in principle, provide a representation of the graph that is isomorphism invariant, i.e. the graph representation should be a function of graph nodes treated as a set. DeepSets (in: Advances in neural information processing systems, pp 3391–3401, 2017) provides a framework to construct a set-aggregation operator with universal approximation properties. In this paper, we propose a DeepSets aggregation operator, based on Self-Organizing Maps (SOM), to transform a set of node-level representations into a single graph-level one. The adoption of SOMs allows to compute node representations that embed the information about their mutual similarity. Experimental results on several real-world datasets show that our proposed approach achieves improved predictive performance compared to the commonly adopted sum aggregation and many state-of-the-art graph neural network architectures in the literature.

scholarly journals SP315ARCHITECT HEPATITIS C VIRUS (HCV) CORE ANTIGEN TEST: A HCV RNA SCREENING ALTERNATIVE IN END-STAGE RENAL DISEASE (ESRD) AND HEMODIALYSIS PATIENTS?

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i450-i450
Author(s):  
Rita Valério Alves ◽  
Rita Abrantes ◽  
Hernâni Gonçalves ◽  
Maria Leonor Gonçalves ◽  
Karina Lopes ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Core Antigen ◽  
Hcv Rna ◽  
Antigen Test ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Clinical and Echocardiographic Factors Associated with Right Ventricular Systolic Dysfunction in Hemodialysis Patients

2016 ◽  
Vol 6 (3) ◽  
pp. 230-236
Author(s):  
Juan Manuel López-Quijano ◽  
Antonio Gordillo-Moscoso ◽  
Jesús Antonio Viana-Rojas ◽  
Jorge Carrillo-Calvillo ◽  
Peter B. Mandeville ◽  
...  
Keyword(s):  
Right Ventricular ◽  
End Stage Renal Disease ◽  
Systolic Dysfunction ◽  
Hemodialysis Patients ◽  
Left Ventricular ◽  
Ventricular Systolic Dysfunction ◽  
Factors Associated ◽  
Relaxation Velocity ◽  
Stage Renal Disease ◽  
End Stage

Background: Chronic kidney disease is a disorder of epidemic proportions that impairs cardiac function. Cardiovascular diseases are the leading cause of death in hemodialysis patients, and the understanding of new nontraditional predictors of mortality could improve their outcomes. Right ventricular systolic dysfunction (RVSD) has recently been recognized as a predictor of cardiovascular death in heart failure and hemodialysis patients. However, the factors contributing to RVSD in hemodialysis patients remain unknown. The aim of this study was to evaluate the clinical and echocardiographic factors associated with RVSD in hemodialysis patients. Methods: A cross-sectional study was conducted in which 100 outpatients with end-stage renal disease on chronic hemodialysis were evaluated. A transthoracic echocardiographic examination was performed at optimal dry weight. Right ventricular systolic function was evaluated using tricuspid annular plane systolic excursion (TAPSE). Clinical and echocardiographic data were recorded for each patient. A multivariate linear logistic regression was created using RVSD (TAPSE <14 mm) as the dependent variable. Results: Fifteen patients with RVSD and 85 patients without RVSD were analyzed. TAPSE had a positive correlation with left ventricular ejection fraction (LVEF) and myocardial relaxation velocity. Independent contributors to RVSD were LVEF (OR 1.14, 95% CI 1.05-1.26), left ventricular mass index (OR 1.02, 95% CI 1.00-1.04), and myocardial relaxation velocity (OR 1.81, 95% CI 1.18-3.19). Conclusions: Echocardiographic factors were significant contributors to RVSD. These measurements could be included as part of the routine workup in all end-stage renal disease patients on hemodialysis.

scholarly journals SUN-205 Prevalence of Cancer in End Stage Renal Disease Hemodialysis Patients

2020 ◽  
Vol 5 (3) ◽  
pp. S285
Author(s):  
F. AlKindi ◽  
S. Jamil ◽  
S. AlKaabi ◽  
M. Hakim ◽  
A. Chaaban ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Stage Renal Disease ◽  
End Stage ◽  
Prevalence Of Cancer

Influence of Recombinant Human Erythropoietin Therapy on Plasma Endothelin-1 Levels during Hemodialysis

2001 ◽  
Vol 24 (6) ◽  
pp. 367-373 ◽  
Author(s):  
I. Stefanidis ◽  
P.R. Mertens ◽  
P. Wurth ◽  
R. Bach ◽  
W. Makropoulos ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Recombinant Erythropoietin ◽  
Human Recombinant Erythropoietin ◽  
Endothelin 1 ◽  
Human Erythropoietin ◽  
Replacement Treatment ◽  
Stage Renal Disease ◽  
End Stage

The correction of anemia with human recombinant erythropoietin (rHuEPO) in end stage renal disease is associated with hypertension in about one third of hemodialysis patients. The pathogenesis of the rHuEPO-induced hypertension is still uncertain, though evidence of the involvement of endothelial cells has emerged. The aim of this study was to determine plasma endothelin-1 during hemodialysis and to compare the endothelin-1 levels in hemodialysis patients with and without rHuEPO substitution. Nineteen stable patients (13 male and 6 female, mean age 62 ± 11 years) with end stage renal disease were studied. Cuprophan dialysers (GFS 12®, Gambro, Lund, Sweden) were used for hemodialysis in all cases. rHuEPO (40U/kg s.c.) was administered to 10 patients. Blood pressure (BP; RR mmHg) and blood volume changes (ΔBV; hemoglobinometry %) were serially measured. Samples were taken before and every hour during hemodialysis. Plasma endothelin-1 was measured by ELISA (R&D Systems, Minneapolis, USA) and corrected for hemoconcentration. Endothelin-1 concentration was elevated before commencement of hemodialysis (1.16 ± 0.36 pg/ml) when compared to healthy controls (ref. 0.3 - 0.9) and increased to 1.47 ± 0.51 pg/ml by the end of the session (p<0.05). In patients under rHuEPO-substitution plasma endothelin-1 was higher when compared to patients without substitution before (1.25 ± 0.3 vs. 1.05 ± 0.3 pg/ml) and at the end of HD (1.62 ± 0.5 vs. 1.28 ± 0.3 pg/ml, p<0.05). There was no difference in BP and ΔBV between the two groups during treatment. Plasma endothelin-1 was higher in hemodialysis patients and there was a continuous rise in plasma endothelin-1 during a session. Comparison of two groups of hemodialysis patients with and without s.c. rHuEPO-replacement treatment revealed a significantly higher plasma endothelin-1 concentration in patients with s.c. rHuEPO treatment. However, the elevated endothelin-1 levels were not accompanied by arterial hypertension.

scholarly journals Effectiveness of Dose Adjustment of Insulin in Type 2 Diabetes among Hemodialysis Patients with End-Stage Renal Disease: A Randomized Crossover Study

2019 ◽  
Vol 2019 ◽  
pp. 1-5
Author(s):  
Amol Singhsakul ◽  
Ouppatham Supasyndh ◽  
Bancha Satirapoj
Keyword(s):  
Type 2 Diabetes ◽  
Renal Disease ◽  
Crossover Study ◽  
End Stage Renal Disease ◽  
Hemodialysis Patients ◽  
Insulin Group ◽  
Stage Renal Disease ◽  
End Stage ◽  
Randomized Crossover Study

Determining insulin requirements for hemodialysis patients with end-stage renal disease (ESRD) is difficult. We performed a randomized crossover study among type 2 diabetes (T2DM) patients with ESRD on continuous hemodialysis and receiving standard insulin for glycemic control. The patients were randomized in 2 groups: daily insulin needed on the day after hemodialysis and a 25% decrease in daily insulin needed on the day after hemodialysis. A total of 51 T2DM patients with ESRD were enrolled. The adjusted-insulin group had higher plasma glucose levels at the 2nd hour of dialysis than those of the nonadjusted-insulin group. Incidence of hypoglycemia per dialysis session (3.3% vs. 0.7%, P=0.02) and symptoms related to hypoglycemia (6.9% vs. 0.7%, P=0.001) were more frequent in the nonadjusted-insulin group. A reduced insulin administration of 25% among T2DM patients undergoing hemodialysis on the day of dialysis was associated with sustained glycemic efficacy and the production of fewer hypoglycemic symptoms. This trial is registered with TCTR20180724002.

Sign in / Sign up

Export Citation Format

Share Document